This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jansen, W. T. M.
Right arrow Articles by Milatovic, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jansen, W. T. M.
Right arrow Articles by Milatovic, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2007, p. 3420-3424, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.00100-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of Telavancin against Gram-Positive Clinical Isolates Recently Obtained in Europe{triangledown}

W. T. M. Jansen,* A. Verel, J. Verhoef, and D. Milatovic

University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands

Received 24 January 2007/ Returned for modification 1 March 2007/ Accepted 18 June 2007

The in vitro activity of telavancin was tested against 620 gram-positive isolates. For staphylococci, MICs at which 50 and 90% of isolates were inhibited (MIC50 and MIC90) were both 0.25 µg/ml, irrespective of methicillin resistance. MIC50 and MIC90 were 0.25 and 0.5 µg/ml for vancomycin-susceptible enterococci and 1 and 2 µg/ml for vancomycin-resistant enterococci, respectively. Streptococcus pneumoniae, group A and B beta-hemolytic streptococci, and viridans streptococci were inhibited by ≤0.12 µg/ml.

* Corresponding author. Mailing address: University Medical Center Utrecht, Eijkman Winkler Institute for Medical Microbiology, Infectious Diseases and Inflammation, G 04.614, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Phone: 31-30-2503566. Fax: 31-30-2541770. E-mail: W.T.M.Jansen{at}umcutrecht.nl

{triangledown} Published ahead of print on 2 July 2007.

Antimicrobial Agents and Chemotherapy, September 2007, p. 3420-3424, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.00100-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Leonard, S. N., Vidaillac, C., Rybak, M. J. (2009). Activity of Telavancin against Staphylococcus aureus Strains with Various Vancomycin Susceptibilities in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations. Antimicrob. Agents Chemother. 53: 2928-2933 [Abstract] [Full Text]  
  • Darouiche, R. O., Mansouri, M. D., Schneidkraut, M. J. (2009). Comparative Efficacies of Telavancin and Vancomycin in Preventing Device-Associated Colonization and Infection by Staphylococcus aureus in Rabbits. Antimicrob. Agents Chemother. 53: 2626-2628 [Abstract] [Full Text]  
  • Brown, D. F. J., Hope, R., Livermore, D. M., Brick, G., Broughton, K., George, R. C., Reynolds, R., on behalf of the BSAC Working Parties on Resistanc, (2008). Non-susceptibility trends among enterococci and non-pneumococcal streptococci from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 62: ii75-ii85 [Abstract] [Full Text]  
  • Draghi, D. C., Benton, B. M., Krause, K. M., Thornsberry, C., Pillar, C., Sahm, D. F. (2008). In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J Antimicrob Chemother 62: 116-121 [Abstract] [Full Text]  
  • Krause, K. M., Renelli, M., Difuntorum, S., Wu, T. X., Debabov, D. V., Benton, B. M. (2008). In Vitro Activity of Telavancin against Resistant Gram-Positive Bacteria. Antimicrob. Agents Chemother. 52: 2647-2652 [Abstract] [Full Text]  
  • Draghi, D. C., Benton, B. M., Krause, K. M., Thornsberry, C., Pillar, C., Sahm, D. F. (2008). Comparative Surveillance Study of Telavancin Activity against Recently Collected Gram-Positive Clinical Isolates from across the United States. Antimicrob. Agents Chemother. 52: 2383-2388 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»